Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAM91A3P (family with sequence similarity 91 member A3, pseudogene) is a transcribed, processed pseudogene in the human genome, annotated by the HGNC (Gene ID: 729182, Ensembl: ENSG00000242352)[1][5][6]. Pseudogenes like FAM91A3P do not encode functional proteins and are generally considered "noncoding" genomic elements. Historically called "junk DNA," recent research has shown that some pseudogenes can be transcribed and may participate in noncoding RNA-based regulation of coding genes, act as miRNA decoys, or contribute to genetic diversity[4]. Evidence of any specific, validated biological function for FAM91A3P itself is lacking, and it is not known to be involved in human disease, biological processes, or therapeutic intervention[3][4][8]. Rarely, pseudogenes can appear as components of fusion transcripts, but clinical significance has not been demonstrated for FAM91A3P[8].\n\nIn summary, FAM91A3P is best classified as a human pseudogene, not a traditional drug target, with no established disease association, interactions, or biomarker utility[1][2][3][4][5][6][8].
No mechanisms of drug action have been associated with FAM91A3P
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 91 member A3, pseudogene (FAM91A3P).